Data sources and applied methods for paclitaxel safety signal discernment

• Published in: Frontiers in cardiovascular medicine 2023, Vol.10, p.1331142-1331142
• Main Authors: Gressler, Laura Elisabeth, Avila-Tang, Erika, Mao, Jialin, Avalos-Pacheco, Alejandra, Shaya, Fadia T, Torosyan, Yelizaveta, Liebeskind, Alexander, Kinard, Madris, Mack, Christina D, Normand, Sharon-Lise, Ritchey, Mary E, Marinac-Dabic, Danica
• Format: Article
• Language: English
• Subjects: balloons; data quality; latemortality; paclitaxel-coated devices; signal discernment; stents
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2023.1331142

Following the identification of a late mortality signal, the Food and Drug Administration (FDA) convened an advisory panel that concluded that additional clinical study data are needed to comprehensively evaluate the late mortality signal observed with the use of drug-coated balloons (DCB) and drug-eluting stent (DES). The objective of this review is to (1) identify and summarize the existing clinical and cohort studies assessing paclitaxel-coated DCBs and DESs, (2) describe and determine the quality of the available data sources for the evaluation of these devices, and (3) present methodologies that can be leveraged for proper signal discernment within available data sources. Studies and data sources were identified through comprehensive searches. original research studies, clinical trials, comparative studies, multicenter studies, and observational cohort studies written in the English language and published from January 2007 to November 2021, with a follow-up longer than 36 months, were included in the review. Data quality of available data sources identified was assessed in three groupings. Moreover, accepted data-driven methodologies that may help circumvent the limitations of the extracted studies and data sources were extracted and described. There were 39 studies and data sources identified. This included 19 randomized clinical trials, nine single-arm studies, eight registries, three administrative claims, and electronic health records. Methodologies focusing on the use of existing premarket clinical data, the incorporation of all contributed patient time, the use of aggregated data, approaches for individual-level data, machine learning and artificial intelligence approaches, Bayesian approaches, and the combination of various datasets were summarized. Despite the multitude of available studies over the course of eleven years following the first clinical trial, the FDA-convened advisory panel found them insufficient for comprehensively assessing the late-mortality signal. High-quality data sources with the capabilities of employing advanced statistical methodologies are needed to detect potential safety signals in a timely manner and allow regulatory bodies to act quickly when a safety signal is detected.